{
    "pubmed_id": 34368647,
    "study_identifier": "PMID34368647_study-01",
    "study_name": "Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms",
    "publication_title": "Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms",
    "study_objective": "To measure seroprevalence using research-grade RBD and spike based ELISA, a commercial RBD and spike-based ELISA, and a commercial NP-based immunoassay",
    "study_description": "Current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological tests are based on the full-length spike (S), the receptor-binding domain (RBD), or the nucleoprotein (NP) as substrates. Here, we used samples from healthcare workers (HCWs) to perform a longitudinal analysis of the antibody responses using a research-grade RBD and spike-based enzyme-linked immunosorbent assay (ELISA), a commercial RBD and spike-based ELISA, and a commercial NP-based chemiluminescent microparticle immunoassay. Seroprevalence ranged around 28% early during the pandemic and a good correlation was observed between RBD and spike-based ELISAs. Modest correlations were observed between NP and both RBD and spike-based assays. The antibody levels in HCWs declined over time; however, the overall seroprevalence measured by RBD and spike-based assays remained unchanged, while the seroprevalence of NP-reactive antibodies significantly declined. Moreover, RBD and spike-based assays effectively detected seroconversion in vaccinees. Overall, our results consolidate the strength of different serological assays to assess the magnitude and duration of antibodies to SARS-CoV-2.",
    "primary_institution_name": "The Icahn School of Medicine at Mount Sinai",
    "study_personnel": [
        {
            "personnel_id": "PMID34368647_personnel-01",
            "honorific": "",
            "last_name": "Mendu",
            "first_name": "Damodara Rao",
            "suffixes": "",
            "organization": "The Icahn School of Medicine at Mount Sinai",
            "orchid_id": "",
            "email": "mendu@mountsinai.org",
            "seronet_title_in_study": "SeroNet Inestigator",
            "role_in_study": "Investigator",
            "site_name": "The Icahn School of Medicine at Mount Sinai"
        },
        {
            "personnel_id": "PMID34368647_personnel-02",
            "honorific": "",
            "last_name": "Simon",
            "first_name": "Viviana",
            "suffixes": "",
            "organization": "The Icahn School of Medicine at Mount Sinai",
            "orchid_id": "",
            "email": "viviana.simon@mssm.edu",
            "seronet_title_in_study": "SeroNet Inestigator",
            "role_in_study": "Investigator",
            "site_name": "The Icahn School of Medicine at Mount Sinai"
        },
        {
            "personnel_id": "PMID34368647_personnel-03",
            "honorific": "",
            "last_name": "Krammer",
            "first_name": "Florian",
            "suffixes": "",
            "organization": "The Icahn School of Medicine at Mount Sinai",
            "orchid_id": "",
            "email": "florian.krammer@mssm.edu",
            "seronet_title_in_study": "SeroNet Inestigator",
            "role_in_study": "Investigator",
            "site_name": "The Icahn School of Medicine at Mount Sinai"
        }
    ],
    "study_file": [
        {
            "study_file_name": "PMID34368647_mmc1.pdf",
            "study_file_description": "Supplementary data",
            "study_file_type": "Study Data"
        },
        {
            "study_file_name": "PMID34368647_Longitudinal seroprevalence, Carreno et al.xlsx",
            "study_file_description": "ELISA assessment values",
            "study_file_type": "Assessment Results"
        },
        {
            "study_file_name": "PMID34368647_Carreno et. al_demographics & Experiment values.xlsx",
            "study_file_description": "Demographics and Experiment results",
            "study_file_type": "Assessment Results"
        },
        {
            "study_file_name": "PMID34368647_v1.2.4.xlsm",
            "study_file_description": "Completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors.",
            "study_file_type": "Study Summary Description"
        },
        {
            "study_file_name": "PMID34368647_JSON.json",
            "study_file_description": "JSON format of completed curation of the study into SeroNet Registry Template which includes SeroNet Study Descriptors",
            "study_file_type": "Study Summary Description"
        }
    ],
    "study_link": [],
    "research_focus": "Infection Response",
    "study_type": "Serosurveillance",
    "keyword": [
        "Immunology",
        "Virology",
        "Chemiluminescent Microparticle Immuno Assay (CMIA)"
    ],
    "clinical_study_design": "Longitudinal Study",
    "in_silico_model_type": "",
    "protocol": {
        "protocol_id": "PMID34368647_protocol-01",
        "protocol_file_name": "PMID34368647_protocol-01.txt",
        "protocol_name": "PMID34368647_protocol-01",
        "protocol_description": "Study Protocol",
        "protocol_type": "Study Protocol"
    },
    "reported_health_condition": [
        "Covid-19"
    ],
    "sars_cov_2_vaccine_type": [
        "N/A"
    ],
    "clinical_outcome_measure": "Measuring seroprevalence using research-grade RBD and spike based ELISA, a commercial RBD and spike-based ELISA, and a commercial NP-based immunoassay",
    "enrollment_start_date": "2020-05-01",
    "enrollment_end_date": "2020-10-01",
    "number_of_study_subjects": 501,
    "age_unit": "Years",
    "minimum_age": "",
    "maximum_age": "",
    "study_human_cohort": [
        {
            "arm_id": "PMID34368647_human_subject-01",
            "arm_name": "Front line health care workers",
            "study_population_description": "Serum samples collected from 501 health care workers in phase 1 and 178 of 501 participants provided serum sample in phase 2. Out of 501, 104 participants with pre Covid-19 infection",
            "arm_type": "Observational",
            "ethnicity": [
                "Not Specified"
            ],
            "race": [
                "Not Specified"
            ],
            "race_specify": [],
            "description": "",
            "sex_at_birth": [
                "Female",
                "Male"
            ],
            "age_event": "Age at enrollment",
            "subject_phenotype": "",
            "assessment_name": [],
            "study_location": [
                "US: New York"
            ],
            "measured_behavioral_or_pyschological_factor": [],
            "measured_social_factor": [],
            "sars_cov_2_symptoms": [],
            "assessment_clinical_and_demographic_data_provenance": [],
            "assessment_demographic_data_types_collected": [],
            "sars_cov_2_history": [
                "Vaccinated",
                "Infected"
            ],
            "sars_cov_2_vaccine_type": [
                "Pfizer BioNTech COVID-19 vaccine ; VO:0004987"
            ],
            "covid_19_disease_severity": [],
            "post_covid_19_symptoms": [],
            "covid_19_complications": []
        }
    ],
    "study_model_cohort": [],
    "planned_visit": [
        {
            "visit_id": "PMID34368647_visit-01",
            "visit_name": "Serum sample collected from health care workers",
            "visit_order_number": 1,
            "visit_min_start_day": 1,
            "visit_max_start_day": "",
            "visit_start_rule": ""
        }
    ],
    "experiment": [
        {
            "arm_id": [
                "PMID34368647_human_subject-01"
            ],
            "associated_first_planned_visit_id": [
                "PMID34368647_visit-01"
            ],
            "assay_type": "ELISA",
            "experiment_name": "Research grade ELISA",
            "experiment_results_file_name": "PMID34368647_Carreno et. al_demographics & Experiment values.xlsx",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Full Length Spike Trimer",
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "Research Use Only",
            "manufacture": "components from multiple manufacturers",
            "catalog_number": "",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34368647_human_subject-01"
            ],
            "associated_first_planned_visit_id": [
                "PMID34368647_visit-01"
            ],
            "assay_type": "ELISA",
            "experiment_name": "Kantaro ELISAs",
            "experiment_results_file_name": "PMID34368647_Carreno et. al_demographics & Experiment values.xlsx",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Full Length Spike Trimer",
                "Receptor Binding Domain (RBD)"
            ],
            "assay_use": "Research Use Only",
            "manufacture": "Kantaro Biosciences",
            "catalog_number": "COV219",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "",
            "assay_reporting_format": "Quantitative"
        },
        {
            "arm_id": [
                "PMID34368647_human_subject-01"
            ],
            "associated_first_planned_visit_id": [
                "PMID34368647_visit-01"
            ],
            "assay_type": "Chemiluminescent Assay",
            "experiment_name": "Abbott Architect CMIA",
            "experiment_results_file_name": "PMID34368647_Carreno et. al_demographics & Experiment values.xlsx",
            "biospecimen_type": [
                "Plasma"
            ],
            "biospecimen_collection_point": [
                "Post-vaccination"
            ],
            "sars_cov_2_antigen": [
                "Nucleocapsid"
            ],
            "assay_use": "Research Use Only",
            "manufacture": "Abbott Laboratories",
            "catalog_number": "06R86",
            "virus_target": [
                "SARS-CoV-2"
            ],
            "antibody_isotype": [
                "IgG"
            ],
            "reporting_units": "Other",
            "assay_reporting_format": "Qualitative"
        }
    ],
    "geriatric_subjects": "No",
    "pediatric_subjects": "No",
    "pregnant_subjects": "No",
    "sars_cov_2_antibodies_measured": "Yes",
    "survey_instrument_shared": "Not Specified",
    "who_disease_severity_scale_used": "Not Specified",
    "inclusion_exclusion": [
        {
            "inclusion_exculusion_id": "PMID34368647_inexcl-01",
            "inclusion_criterion": "SARS-CoV-2 Antibodies Measured",
            "inclusion_criterion_category": "inclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34368647_inexcl-02",
            "inclusion_criterion": "Pediatric subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34368647_inexcl-03",
            "inclusion_criterion": "Pregnant subjects",
            "inclusion_criterion_category": "exclusion"
        },
        {
            "inclusion_exculusion_id": "PMID34368647_inexcl-04",
            "inclusion_criterion": "Geriatric subjects",
            "inclusion_criterion_category": "exclusion"
        }
    ]
}
